Journal of neuro-oncology

publication venue for

Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. 2011
Bilateral phrenic nerve dysfunction: a late complication of mantle radiation. 2010
Post-radiotherapy myelitis observed in an AIDS patient with a meningioma: case report and review of the literature. 1999
Safety and efficacy of Cesium-131 brachytherapy for brain tumors. 2023
Additive risk of surgical site infection from more than one risk factor following craniotomy for tumor. 2023
Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.. 162. 2023
Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases.. 159. 2022
Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era? 2022
Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. 2022
Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. 2022
Familial colloid cysts: not a chance occurrence. 2022
Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation.. 155. 2021
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. 2021
Impact of the COVID-19 pandemic on neuro-oncology outcomes.. 154. 2021
Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.. 154. 2021
The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes.. 153. 2021
3D whole-brain metabolite imaging to improve characterization of low-to-intermediate grade gliomas.. 153. 2021
Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas.. 153. 2021
Development of new brain metastases in triple negative breast cancer.. 152. 2021
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.. 148. 2020
Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology.. 147. 2020
Racial and socioeconomic correlates of treatment and survival among patients with meningioma: a population-based study.. 147. 2020
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.. 146. 2019
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.. 146. 2019
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.. 144. 2019
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.. 144. 2019
Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system.. 143. 2019
Tumor control and survival in patients with ten or more brain metastases treated with stereotactic radiosurgery: a retrospective analysis.. 143. 2019
High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases.. 142. 2019
EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.. 142. 2019
Tubular brain tumor biopsy improves diagnostic yield for subcortical lesions.. 141. 2018
Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials.. 140. 2018
Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.. 140. 2018
Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.. 139. 2018
Patterns of relapse for children with localized intracranial ependymoma.. 138. 2018
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.. 138. 2018
Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.. 138. 2018
A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.. 136. 2017
Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma.. 136. 2017
Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.. 136. 2017
Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.. 136. 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.. 136. 2017
SHP2 regulates proliferation and tumorigenicity of glioma stem cells.. 135. 2017
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.. 135. 2017
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.. 134. 2017
Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors.. 134. 2017
Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system.. 133. 2017
Expression and function of ABCG2 and XIAP in glioblastomas.. 133. 2017
Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.. 133. 2017
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.. 133. 2017
Comparing available criteria for measuring brain metastasis response to immunotherapy.. 132. 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.. 132. 2017
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.. 130. 2016
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.. 130. 2016
Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.. 129. 2016
Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.. 127. 2016
Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study.. 127. 2016
Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging.. 127. 2016
The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.. 127. 2016
Quantitative imaging of magnesium distribution at single-cell resolution in brain tumors and infiltrating tumor cells with secondary ion mass spectrometry (SIMS).. 127. 2015
Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.. 127. 2015
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.. 127. 2015
Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.. 125. 2015
A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.. 125. 2015
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.. 125. 2015
Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.. 123. 2015
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.. 123. 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).. 123. 2015
Diagnostic yield of echocardiography in cancer patients with ischemic stroke.. 123. 2015
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.. 122. 2014
Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling.. 121. 2014
Ipilimumab and whole brain radiation therapy for melanoma brain metastases.. 121. 2014
Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.. 120. 2014
Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.. 120. 2014
Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation.. 119. 2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma.. 117. 2014
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.. 116. 2013
Neuropilin-2 contributes to tumorigenicity in a mouse model of Hedgehog pathway medulloblastoma.. 115. 2013
Vemurafenib and radiation therapy in melanoma brain metastases.. 113. 2013
Steroid management in newly diagnosed glioblastoma.. 113. 2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.. 112. 2013
The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme.. 112. 2013
B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.. 111. 2012
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).. 111. 2012
Continuous daily sunitinib for recurrent glioblastoma.. 111. 2012
Post-treatment T1 shortening in primary CNS lymphoma.. 111. 2012
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.. 110. 2012
Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease.. 110. 2012
Atypical and anaplastic meningiomas treated with bevacizumab.. 109. 2012
Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis.. 108. 2012
Refining endpoints in brain tumor clinical trials.. 108. 2012
Seizure prophylaxis and melanoma brain metastases.. 108. 2012
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.. 107. 2011
Use of recombinant tissue plasminogen activator in cancer patients with acute stroke.. 107. 2011
Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma.. 107. 2011
mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.. 106. 2011
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.. 106. 2011
Herpes simplex encephalitis in patients with cancer.. 105. 2011
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.. 105. 2011
Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction.. 104. 2011
Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging.. 104. 2011
Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.. 102. 2010
Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.. 99. 2010
Quality of life and behavioral follow-up study of Head Start I pediatric brain tumor survivors.. 101. 2010
Inverse association of PPARγ agonists use and high grade glioma development.. 100. 2010
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.. 100. 2010
Overexpression and activation of epidermal growth factor receptor in hemangioblastomas.. 99. 2010
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.. 97. 2009
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells.. 97. 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.. 96. 2009
Genetically engineered T cells to target EGFRvIII expressing glioblastoma.. 94. 2009
Glioma-associated endothelial cells are chemoresistant to temozolomide.. 95. 2009
Quantification of dispersion of Gd-DTPA from the initial area of enhancement into the peritumoral zone of edema in brain tumors.. 94. 2009
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.. 94. 2009
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.. 94. 2009
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).. 92. 2008
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.. 91. 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.. 91. 2008
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).. 91. 2008
Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.. 88. 2008
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.. 87. 2007
Longitudinal cognitive follow-up in low grade gliomas.. 86. 2007
Capecitabine therapy of central nervous system metastases from breast cancer.. 85. 2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.. 85. 2007
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.. 81. 2006
Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.. 82. 2006
Cognitive functions in low-grade gliomas: disease and treatment effects.. 81. 2006
PTEN inhibits adrenomedullin expression and function in brain tumor cells.. 79. 2006
Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.. 76. 2006
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.. 76. 2006
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.. 74. 2005
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.. 71. 2005
Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.. 71. 2005
Interstitial infusion of IL13-PE38QQR in the rat brain stem.. 67. 2004
Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine.. 67. 2004
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.. 65. 2003
Effect of hyperosmolar mannitol on convection-enhanced delivery into the rat brain stem.. 58. 2002
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. 58. 2002
Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model.. 56. 2002
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.. 46. 2000
High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors.. 44. 1999
Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy.. 37. 1998
High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.. 37. 1998
Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine.. 36. 1998
Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.. 35. 1997
Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.. 35. 1997
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.. 35. 1997
A rat model of leptomeningeal human neoplastic xenografts.. 34. 1997
Adeno-associated viral vector gene transfer into leptomeningeal xenografts.. 34. 1997
Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma.. 34. 1997
Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results.. 33. 1997
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.. 32. 1997
Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation.. 24. 1995
Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.. 19. 1994
Staurosporine differentially inhibits glioma versus non-glioma cell lines.. 16. 1993
Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.. 15. 1993
p53 gene mutations in primary lung tumors are conserved in brain metastases.. 14. 1992
Low dose rate radiotherapy for transplantable gliosarcoma in the rat brain.. 9. 1990
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.. 7. 1989
The combined use of radiation therapy and lonidamine in the treatment of brain metastases.. 7. 1989
Apparent glucose utilization in Walker 256 metastatic brain tumors.. 4. 1986
Apparent glucose utilization in Walker 256 metastatic brain tumors.. 3. 1985
Chemotherapy trials in recurrent primary intracranial germ cell tumors.. 3. 1985
Local blood flow in Walker 256 metastatic brain tumors.. 2. 1984
Local blood-to-tissue transport in Walker 256 metastatic brain tumors.. 2. 1984
Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model.. 2. 1984
Brain metastases from colon cancer.. 1. 1983
Summary of the U.S.-Japanese Conference on brain tumor therapy.. 1. 1983
Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy.. 144. 2019
Management of late extraneural recurrence of medulloblastoma without high-dose chemotherapy.. 124. 2015
Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's disease.. 82. 2007
Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons. 2021
The evolution of stereotactic radiosurgery in neurosurgical practice. 2021
Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients. 2017
Resection of pituitary tumors: endoscopic versus microscopic. 2016
Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review. 2014
Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease. 2010
Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. 2010
Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature. 2005
Brain metastases: epidemiology and pathophysiology. 2005
Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. 2005
Surgery of brain metastases--is there still a place for it? 2005
Brachytherapy for brain tumors. 2005
Intramedullary ependymomas: clinical presentation, surgical treatment strategies and prognosis. 2000
Non-neoplastic intramedullary pathology. Diagnostic dilemma: to Bx or not to Bx. 2000
High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. 1996
Current treatment of thalamic gliomas in children. 1996
The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. 1996
Brachytherapy for central nervous system tumors. 2022
Leptomeningeal metastases: the future is now. 2022
Update on management of craniopharyngiomas. 2021
Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. 1999
Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. 1995

VIVO Weill Cornell Medical College

Journal of neuro-oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)